Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (611-620 of 713) with videos related to

Pageof 72
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetMichele Baccarani, Jorge Cortes, Fabrizio Pane, et al.
Cancer|December 7, 2018
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypesPrajwal C Boddu, Tapan M Kadia, Guillermo Garcia-Manero, et al.
Blood|April 13, 2006
Lenalidomide therapy in myelofibrosis with myeloid metaplasiaAyalew Tefferi, Jorge Cortes, Srdan Verstovsek, et al.
Cancer|February 28, 2006
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaDeborah A Thomas, Stefan Faderl, Susan O'Brien, et al.
JAMA Network Open|December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid LeukemiaAaron N Winn, Ehab Atallah, Jorge Cortes, et al.
Blood Advances|December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AMLNicholas J Short, Hind Rafei, Naval Daver, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2016
Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous LeukemiaBetül Oran, Jorge Cortes, Amer Beitinjaneh, et al.
Cancer|October 12, 2018
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvageElias Jabbour, Koji Sasaki, Farhad Ravandi, et al.
Cancer|May 17, 2002
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent courseSrdan Verstovsek, Hui Lin, Hagop Kantarjian, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Pageof 72

Showing results (611-620 of 713) with videos related to

Sort By:
Pageof 72
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetMichele Baccarani, Jorge Cortes, Fabrizio Pane, et al.
Cancer|December 7, 2018
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypesPrajwal C Boddu, Tapan M Kadia, Guillermo Garcia-Manero, et al.
Blood|April 13, 2006
Lenalidomide therapy in myelofibrosis with myeloid metaplasiaAyalew Tefferi, Jorge Cortes, Srdan Verstovsek, et al.
Cancer|February 28, 2006
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaDeborah A Thomas, Stefan Faderl, Susan O'Brien, et al.
JAMA Network Open|December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid LeukemiaAaron N Winn, Ehab Atallah, Jorge Cortes, et al.
Blood Advances|December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AMLNicholas J Short, Hind Rafei, Naval Daver, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2016
Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous LeukemiaBetül Oran, Jorge Cortes, Amer Beitinjaneh, et al.
Cancer|October 12, 2018
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvageElias Jabbour, Koji Sasaki, Farhad Ravandi, et al.
Cancer|May 17, 2002
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent courseSrdan Verstovsek, Hui Lin, Hagop Kantarjian, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Pageof 72